Showing 1 - 10 of 18
We explore how firms respond to downstream product shocks. We find that affected firms increase R&D and make additional safety-related investments in their existing assets-in-place. These investments vary with firm capabilities and across shock severity. Competitors appear to vicariously learn...
Persistent link: https://www.econbiz.de/10014635666
We study the effect of the COVID-19 pandemic on chronic disease drug adherence. Focusing on asthma, we use a database that tracks the vast majority of prescription drug claims in the U.S. from 2018 to 2020. Using a difference-in-differences empirical specification, we compare monthly drug...
Persistent link: https://www.econbiz.de/10014226165
Are some management practices akin to a technology that can explain firm and national productivity, or do they simply reflect contingent management styles? We collect data on core management practices from over 11,000 firms in 34 countries. We find large cross-country differences in the adoption...
Persistent link: https://www.econbiz.de/10012456349
Managers of private entrepreneurial firms face obstacles in raising capital both in placing a value on a firm and conveying value to investors. These problems are exacerbated when the firm is small, has limited assets (except for human capital) and has yet to have a lead product. In such cases...
Persistent link: https://www.econbiz.de/10012464045
We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...
Persistent link: https://www.econbiz.de/10012481442
Prior literature has established a link between changes in market size and pharmaceutical innovation; whether a link exists with scientific research remains an open question. If upstream research is not responsive to these changes, the kinds of scientific discoveries that flow into future drug...
Persistent link: https://www.econbiz.de/10012533407
Despite the fact that one of the main goals of corporate venture capital (CVC) investments in high-tech industries is to gain a window on future technologies, the relationship between CVC investments and strategies used to acquire technologies in the markets, such as licensing, has not been...
Persistent link: https://www.econbiz.de/10012457244
Existing research has focused on why and when firms may choose to access the external technology market. Surprisingly, however, less is known about the reliability of the patents attached to these external technologies in the face of litigation. "Weak" external patents expose a firm to the...
Persistent link: https://www.econbiz.de/10012457563
During the last years more and more discussions came up about the contribution of technology-oriented and technology-intensive industries for the economic development and employment. This paper examines the foundation dynamic and the regional clustering of various technology-oriented sectors in...
Persistent link: https://www.econbiz.de/10011620601
Persistent link: https://www.econbiz.de/10013428015